The Need for Pharmacopeial Harmonization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Need for Pharmacopeial Harmonization
In the context of international trade, the need to develop global quality standards for medicines is increasing.


Pharmaceutical Technology
Volume 37, Issue 4, pp. 36-38


Susanne Keitel, PhD
Quality standards are vital instruments in the context of marketing authorization and market surveillance, and they facilitate free movement and trade of medicines among countries and regions. The European Pharmacopoeia (Ph. Eur.) has always been at the forefront of the harmonization of quality standards. Indeed, almost 50 years ago, the “founding fathers” of the Convention on the elaboration of a European pharmacopoeia had already identified the need to harmonize quality requirements for medicinal products on the European market. They also acknowledged the difficulties in retrospective harmonization and so decided to begin establishing the Ph. Eur. by focusing on substances for which there were no existing standards in member states. The Convention was signed by eight countries in 1964 and, today has 38 signatory parties—37 states and the European Union. The success of this pan-European undertaking and its impact on a global scale is demonstrated by the 24 observers to the Convention, comprised of 23 countries from all around the world and the World Health Organization (WHO). The positive experience gained in prospective harmonization and the trust and mutual confidence developed between participants in the early years has, in the meantime, also been translated into retrospective harmonization. Today, topics that are of interest to more than one member state end up on the work program of the European Pharmacopoeia Commission, regardless of whether or not a national standard already exists.

A changing industry

Since the establishment of the European Pharmacopoeia in the 1960s, the world, and with it the pharmaceutical industry, has changed significantly. International harmonization among the three pharmacopoeias of Europe, Japan, and the United States (i.e., the three regions that started the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [ICH]) was, therefore, a logical development. Harmonization activities among the European, Japanese, and US pharmacopoeias began in 1989 with the establishment of the Pharmacopoeial Discussion Group (PDG); an informal harmonization initiative between these pharmacopoeias parallel to ICH. In fact, it was a prerequisite for the ICH Steering Committee to agree on the elaboration of the ICH Guideline Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products that the PDG committed to harmonizing the 11 general methods referred to in the document at that time and not to make unilateral changes once harmonization was complete. The ICH Q6A guideline includes a specific reference to the work of the PDG in chapter 2.8 “Pharmacopoeial Tests and Acceptance Criteria.”

Where harmonization of general chapters is carried out, the aim is to arrive at interchangeable methods or requirements so that demonstration of compliance using a general chapter from one of the three pharmacopeias implies that the same result would be obtained using the general chapter of any of the other two PDG pharmacopeias. However, the activities of the PDG in harmonizing general methods have not been limited to the Q6A methods; a wide range of general methods (35) has since been added to the work program. These include methods, such as chromatography, that are crucial for the quality control of medicines and a prerequisite for further harmonization of specific monographs. Besides the harmonization of general methods, the PDG has also been working on monographs for widely used excipients. Currently, 62 such excipients are included in its work program. Clearly, the purpose of harmonizing a monograph is to arrive at identical requirements for all attributes of the product in question.

To date, 28 of the 35 general methods and 43 of the 62 excipient monographs have been harmonized. Detailed information on the work program of the PDG is published in Pharmeuropa and the respective forums of the other two PDG pharmacopeias. In addition, the Ph. Eur. contains a specific General Chapter 5.8., Pharmacopoeial harmonization, that provides more information on the outcome of harmonization. This chapter was revised by the Ph.Eur. Commission in November 2012 to provide further support to users by highlighting information on any nonharmonized attributes/provisions and on any local requirements (i.e., attributes that are present only in the Ph. Eur. text). Non-harmonized attributes/provisions are placed between black diamonds in the corresponding Ph. Eur. texts, and the local requirements are marked by white diamonds ().

The PDG has often been criticized of slow progress. However, it has to be acknowledged that the three pharmacopeias have differing legal statuses; the Japanese Pharmacopoeia is part of the Japanese government’s Ministry of Health, Labour and Welfare; the European Pharmacopoeia is part of the Council of Europe (an inter-governmental organization); while the US Pharmacopeia Convention (USP) is a private, not-for-profit organization that is independent of the US government. In addition, all three are embedded in their specific national/regional regulatory frameworks that, after more than 20 years of activity at the ICH level, are only partially harmonized.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here